Il-23/Th17 cell pathway: A promising target to alleviate thymic inflammation maintenance in myasthenia gravis
- 1 March 2019
- journal article
- research article
- Published by Elsevier in Journal of Autoimmunity
- Vol. 98, 59-73
Abstract
No abstract availableKeywords
Funding Information
- FIGHT-MG (HEALTH-2009-242-210)
- Association Française contre les Myopathies
- CONACyT
This publication has 54 references indexed in Scilit:
- Induction and molecular signature of pathogenic TH17 cellsNature Immunology, 2012
- IL‐23: One cytokine in control of autoimmunityEuropean Journal of Immunology, 2012
- Podoplanin: emerging functions in development, the immune system, and cancerFrontiers in Immunology, 2012
- Th17 Cells Induce Ectopic Lymphoid Follicles in Central Nervous System Tissue InflammationImmunity, 2011
- The thymus in myasthenia gravis: Site of “innate autoimmunity”?Muscle & Nerve, 2011
- IL-23 drives a pathogenic T cell population that induces autoimmune inflammationJournal of Experimental Medicine, 2005
- Expression of Transforming Growth Factor‐β1 in Thymus of Myasthenia Gravis PatientsAnnals of the New York Academy of Sciences, 2003
- Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature, 2003
- T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines.Journal of Experimental Medicine, 1996
- In vitro interleukin-1 (IL-1) production in thymic hyperplasia and thymoma from patients with myasthenia gravisJournal of Clinical Immunology, 1991